Humphrey Tomlinson - Direct Line General Counsel, Company Secretary
DIISY Stock | USD 13.64 0.38 2.87% |
Executive
Mr. Humphrey Tomlinson is General Counsel of Direct Line Insurance Group Plc. He joined the Group in 2011 and has over 25 years experience as a solicitor. Humphrey is responsible for the Group Legal function and oversees a range of areas of legal advice and services. During Humphreys leadership of the Group Legal function and its team of lawyers, he has overseen the legal aspects of the Groups 500 million debt issue, the IPO and the related separation of the Group from RBS Group, the sale of the Groups International division, and the 2017 350 million Restricted Tier 1 debt issue. He is also a Director of DLG Legal Services Limited. Humphreys experience includes advising on corporate and commercial matters, steering corporate transactions in the UK and internationally, managing legal risk and dealing with corporate governance issues. Before joining the Group, Humphrey was Group Legal Director at RSA and prior to that he was a corporate lawyer with the City law firm, Ashurst Morris Crisp. He is a graduate of the University of Oxford. since 2014.
Tenure | 11 years |
Phone | 44 1132 920 667 |
Web | https://www.directlinegroup.co.uk |
Direct Line Management Efficiency
The company has return on total asset (ROA) of 0.0251 % which means that it generated a profit of $0.0251 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1027 %, meaning that it generated $0.1027 on every $100 dollars invested by stockholders. Direct Line's management efficiency ratios could be used to measure how well Direct Line manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Nachiappan Chidambaram | Lipocine | 56 | |
Jeffrey Jensen | Inhibrx | N/A | |
Tabitha Bailey | Sonida Senior Living | 39 | |
Anne DVM | Molecular Partners AG | N/A | |
JD Esq | Acumen Pharmaceuticals | 54 | |
David MBA | Inhibrx | N/A | |
Caitlin Lowie | Ardelyx | N/A | |
Elizabeth Esq | Ardelyx | 61 | |
Robyn MA | Acumen Pharmaceuticals | N/A | |
Charbel PharmD | Inhibrx | N/A | |
Renate Gloggner | Molecular Partners AG | 55 | |
Robert Hendriks | Molecular Partners AG | N/A | |
Ashraf Amanullah | Inhibrx | 57 | |
Michael Karicher | Sonida Senior Living | 55 | |
Brendan Eckelman | Inhibrx | 46 | |
MPH MD | Ardelyx | 61 | |
Joseph Reilly | Ardelyx | 51 | |
Mike Kelliher | Ardelyx | 48 | |
Maribeth Neelis | Sonida Senior Living | N/A | |
Josep Garcia | Inhibrx | N/A | |
MD MBA | Molecular Partners AG | N/A |
Management Performance
Return On Equity | 0.1 | |||
Return On Asset | 0.0251 |
Direct Line Insurance Leadership Team
Elected by the shareholders, the Direct Line's board of directors comprises two types of representatives: Direct Line inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Direct. The board's role is to monitor Direct Line's management team and ensure that shareholders' interests are well served. Direct Line's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Direct Line's outside directors are responsible for providing unbiased perspectives on the board's policies.
Paul Smith, Investor Director | ||
Neil Manser, CFO Director | ||
Jessie Burrows, Service Sales | ||
Ash Jokhoo, Chief Officer | ||
Humphrey Tomlinson, General Counsel, Company Secretary | ||
Victoria Wallis, Chief Officer | ||
Jonathan Greenwood, Managing Director of Commercial | ||
Jade Trimbee, Co Mang | ||
Jennifer Thomas, Head Communications | ||
Penelope ACA, CEO Director |
Direct Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Direct Line a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.1 | |||
Return On Asset | 0.0251 | |||
Profit Margin | 0.09 % | |||
Operating Margin | 0.11 % | |||
Current Valuation | 2.85 B | |||
Shares Outstanding | 327.85 M | |||
Price To Earning | 7.19 X | |||
Price To Book | 1.08 X | |||
Price To Sales | 1.09 X | |||
Revenue | 3.24 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Direct Pink Sheet Analysis
When running Direct Line's price analysis, check to measure Direct Line's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Direct Line is operating at the current time. Most of Direct Line's value examination focuses on studying past and present price action to predict the probability of Direct Line's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Direct Line's price. Additionally, you may evaluate how the addition of Direct Line to your portfolios can decrease your overall portfolio volatility.